To Evaluate the Feasibility, Preliminary Safety and Performance of Rezūm System in BPH Treatment in China
To Evaluate the Feasibility, Preliminary Safety and Performance of Rezūm System in BPH Treatment in China
A real world study to evaluate the feasibility, preliminary safety and performance of Rezūm
 system in BPH treatment in China Rezūm RWS study
This RWS study is to evaluate the feasibility, preliminary safety and performance of Rezūm
 system in BPH treatment in China, to generate local real world data from a Chinese BPH
 population.

 The Rezūm System is intended to relieve symptoms, obstructions, and reduce prostate tissue
 associated with BPH. It is indicated for men ≥50 years of age with a prostate volume ≥ 30cm3
 and ≤80cm3. The Rezūm System is also indicated for treatment of prostate with hyperplasia of
 the central zone and/or a median lobe.
Inclusion Criteria:

 -  The subjects will provide written informed consent form and agree to data collection.

 -  The subjects who were diagnosed as BPH and treated by Rezūm procedure in Hainan
 medical pilot zone will be enrolled in this study.

 Exclusion Criteria:

 -  This is a retrospective study without any formal exclusion criteria.